It was discovered that antigen-binding molecules comprising (1) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions and (2) a T cell receptor complex-binding domain, crosslink T cells with the cells having immune response-suppressing functions and induce damage to the cells having immune response-suppressing functions to thereby exhibit more superior antitumor effects than conventional antigen-binding molecules. It was also discovered that combined use of the antigen-binding molecules and other anticancer agents further increases the antitumor effects.
